{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:28:07Z","timestamp":1794014887807,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clgc.2021.11.004","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T11:31:05Z","timestamp":1636716665000},"page":"53-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients"],"prefix":"10.1016","volume":"20","author":[{"given":"Dylan J.","family":"Martini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean T.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-3058","authenticated-orcid":false,"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-9294","authenticated-orcid":false,"given":"Julie M.","family":"Shabto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8730-6859","authenticated-orcid":false,"given":"Ogul E.","family":"Uner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Anders","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-0906","authenticated-orcid":false,"given":"Jacqueline T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta Anne","family":"Russler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0611-7106","authenticated-orcid":false,"given":"Lauren","family":"Yantorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie M.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Nazha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj A.","family":"Master","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley C.","family":"Carthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.11.004_bib0001","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/phar.2076","article-title":"Cabozantinib: a multitargeted oral tyrosine kinase inhibitor","volume":"38","author":"Markowitz","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.clgc.2021.11.004_bib0002","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/cncr.32802","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"126","author":"Henley","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.11.004_bib0003","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.11.004_bib0004","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.11.004_bib0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.11.004_bib0006","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib","volume":"56","author":"Lacy","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clgc.2021.11.004_bib0007","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.2017-0335","article-title":"Management of adverse events associated with Cabozantinib therapy in renal cell carcinoma","volume":"23","author":"Schmidinger","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2021.11.004_bib0008","unstructured":"FDA Approved Drug Products [Internet]. Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf. [cited 2021 Apr 28."},{"key":"10.1016\/j.clgc.2021.11.004_bib0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2021.11.004_bib0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ctrv.2018.04.007","article-title":"Management of treatment-related toxicities in advanced medullary thyroid cancer","volume":"66","author":"Brose","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2021.11.004_bib0011","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00280-018-3579-7","article-title":"Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma","volume":"81","author":"Lacy","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2021.11.004_bib0012","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40267-018-0547-6","article-title":"Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use","volume":"34","author":"Lyseng-Williamson","year":"2018","journal-title":"Drugs Ther Perspect"},{"key":"10.1016\/j.clgc.2021.11.004_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.774","article-title":"Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study","volume":"31","author":"Pal","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.11.004_bib0014","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/0192623312464311","article-title":"On-target and off-target-based toxicologic effects","volume":"41","author":"Rudmann","year":"2013","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.clgc.2021.11.004_bib0015","first-page":"249","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2021.11.004_bib0016","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2015.368","article-title":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients","volume":"113","author":"Donskov","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2021.11.004_bib0017","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1756-9966-29-95","article-title":"Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib","volume":"29","author":"Jain","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clgc.2021.11.004_bib0018","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.21873\/anticanres.12927","article-title":"Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients","volume":"38","author":"Grabowski","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2021.11.004_bib0019","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1200\/JCO.2016.66.7311","article-title":"Body mass index and metastatic renal cell carcinoma: clinical and biological correlations","volume":"34","author":"Albiges","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.11.004_bib0020","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"Antoun","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.11.004_bib0021","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2326-6066.CIR-17-0220","article-title":"Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1\/PD-L1 therapy for immune-related adverse events","volume":"6","author":"Martini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clgc.2021.11.004_bib0022","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2021.11.004_bib0023","doi-asserted-by":"crossref","first-page":"S645","DOI":"10.1200\/JCO.2019.37.7_suppl.645","article-title":"Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients","volume":"37","author":"Elias","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.11.004_bib0024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12032-018-1239-8","article-title":"The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Kucharz","year":"2019","journal-title":"Med Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321002056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321002056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:19Z","timestamp":1761564859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321002056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1558767321002056"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.11.004","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}